Pharma BD Deal Intelligence

Link Healthcare Singapore / Shionogi & Co., Ltd.

2026 · Licensing/Option · Complete

Shionogi & Co., Ltd. granted Link Healthcare Singapore exclusive rights to develop and commercialize cefiderocol in Singapore and Malaysia. Cefiderocol is a first-in-class siderophore cephalosporin for serious Gram-negative bacterial infections that may be resistant to other antibiotics. The agreement extends an existing Shionogi relationship with the Link/Clinigen group, which received cefiderocol rights for Australia and New Zealand under a March 2025 agreement. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →